Mylan Appeals Dismissal Of Prilosec Antitrust Claims

Law360, New York (June 22, 2010, 2:08 PM EDT) -- Three years after a court ruled that Mylan Laboratories Inc. did not infringe patents for AstraZeneca AB's heartburn drug Prilosec, Mylan is taking its allegations that AstraZeneca violated antitrust law by filing sham patent suits to the U.S. Court of Appeals for the Federal Circuit.

On Friday, Mylan notified the U.S. District Court for the Southern District of New York that it was appealing the court's ruling dismissing its antitrust claims and denying its motion for attorneys' fees.

On May 19, Judge Barbara S. Jones of...
To view the full article, register now.